Nexentis Technologies Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| NXTS | NEXR | NFX.L | XBIO | NXL | NCEL | |
|---|---|---|---|---|---|---|
| Market cap | 1.32M | 1.04M | 2.87M | 4.71M | 1.64M | 14.79M |
| P/E (TTM) | — | 0.0 | — | — | — | 4.9 |
| Forward P/E | — | — | — | -3.0 | -0.2 | -4.3 |
| Price/book | 0.4 | 0.0 | 1.1 | 0.8 | 0.8 | 2.3 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −97.40% | −99.93% | −72.97% | −26.10% | −95.84% | −43.83% |
| Today | −2.46% | +4.52% | +10.00% | −3.37% | +1.30% | −3.03% |
The closest companies by business and industry (Agricultural Inputs). Prices may be delayed up to 15 min.
Latest news
All NXTS news ›New web tool brings molecular docking to any researcher’s browser
University of Tsukuba researchers have launched "Anyone Can Dock," a browser-based platform that automates molecular docking workflows and adds AI-assisted interpretation for non-specialists.
Eight Practical Tips for Navigating the Reactome Pathway Knowledgebase
A new PLOS Computational Biology guide from the Reactome curation team offers eight practical tips for exploring, analyzing and reusing the curated pathway knowledgebase. Eight Practical Tips for Navigating the Reactome Pathway…
Analyzing Nexentis Technologies (NASDAQ:NXTS) & Royalty Pharma (NASDAQ:RPRX)
Posted by Danessa Lincoln on Oct 27th, 2026 Nexentis Technologies (NASDAQ:NXTS – Get Free Report) and Royalty Pharma (NASDAQ:RPRX – Get Free Report) are both healthcare companies, but which is the better business? We will contrast the two…
New software unlocks secrets of cell signaling
SMART, a new software package, can make studying signaling processes significantly easier. Results could accelerate research in fields across the life sciences, such as systems biology, pharmacology and biomedical engineering. New software…
Critical Survey: Nexentis Technologies (NASDAQ:NXTS) versus Palisade Bio (NASDAQ:PALI)
Posted by Michael Walen on Oct 24th, 2026 Nexentis Technologies (NASDAQ:NXTS – Get Free Report) and Palisade Bio (NASDAQ:PALI – Get Free Report) are both small-cap healthcare companies, but which is the better business? We will contrast…
Nexentis Technologies director awarded 19,375 shares
Ronen Rosenbloom's October 15, 2026 award left reported holdings at 19,640 shares, held indirectly by a trust, according to the director's Form 4. - [Form 4] Nexentis Technologies Inc. Insider Trading Activity Nexentis Technologies…
Nexentis Technologies CFO awarded 51,000 restricted shares
Post-award holdings were 60,198 shares following the October 15, 2026 grant under the Save Foods, Inc. 2022 Share Incentive Plan, reported at $0 per share. - [Form 4] Nexentis Technologies Inc. Insider Trading Activity Nexentis…
Nexentis Technologies CEO awarded 101,549 shares
The October 15, 2026 award under the Save Foods, Inc. 2022 Share Incentive Plan left David Palach's reported trust-held position at 120,000 shares. - [Form 4] Nexentis Technologies Inc. Insider Trading Activity Nexentis Technologies CEO…
Israel Yakov Berenstein Acquires 19,375 Restricted Shares in Nexentis Technologies
Did Stronger Steel Earnings Put Nucor (NYSE:NUE) in Focus? Did Stronger Aluminum Earnings Put Alcoa (NYSE:AA) in Focus? On October 19, 2026, Director Israel Yakov Berenstein submitted a statement of changes in beneficial ownership to the…
Nexentis Technologies Expands MitoCareX Bioinformatics Capabilities to Add Disease-Pathway Analysis to Drug-Discovery Platform
MitoCareX is expanding its bioinformatics expertise to enhance the analysis of disease biology in its drug-discovery platform. The goal is to incorporate disease-related insights early in the discovery process for better target evaluation…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- stocktitan.net9
- themarketsdaily.com2
- kalkinemedia.com1
- quiverquant.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 13 articles, not a forecast.